



## Clinical trial results:

### A Randomized, Non-Inferiority, Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Abaloparatide-sMTS for the Treatment of Postmenopausal Women with Osteoporosis

#### Summary

EudraCT number	2019-004807-11
Trial protocol	HU DK BG
Global end of trial date	09 November 2021

#### Results information

Result version number	v1
This version publication date	25 December 2022
First version publication date	25 December 2022

#### Trial information

##### Trial identification

Sponsor protocol code	BA058-05-021
-----------------------	--------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04064411
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Radius Health, Inc.
Sponsor organisation address	22 Boston Wharf Road, 7th floor, Boston, MA, United States, 02210
Public contact	Radius Contact Information, Radius Health Inc., 1 6175514000, info@radiuspharm.com
Scientific contact	Radius Contact Information, Radius Health, Inc., 1 6175514000, info@radiuspharm.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 June 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	05 October 2021
Global end of trial reached?	Yes
Global end of trial date	09 November 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

A 12-month study to compare the efficacy and safety of abaloparatide-solid microstructured transdermal system (sMTS) with abaloparatide-subcutaneous (SC).

Protection of trial subjects:

The study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki, the guidelines for current Good Clinical Practice International Conference on Harmonization (ICH), the US Food and Drug Administration Code of Federal Regulations, and all other applicable local regulatory and ethical requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 August 2019
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 352
Country: Number of subjects enrolled	Denmark: 16
Country: Number of subjects enrolled	Hungary: 29
Country: Number of subjects enrolled	Poland: 114
Worldwide total number of subjects	511
EEA total number of subjects	159

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	111

From 65 to 84 years	400
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Eligible female participants were randomized to a 12-month open-label study treatment at 83 study centers in the United States, Denmark, Hungary, and Poland.

### Pre-assignment

Screening details:

During the Screening Period, participants were assessed to determine if their current medical history and status was consistent with criteria for study entrance. On Day 1 of the Treatment Period, participants were randomized in a 1:1 ratio to either abaloparatide subcutaneous (SC) or abaloparatide solid microstructured transdermal system (sMTS).

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Assessor <sup>[1]</sup>

Blinding implementation details:

Treatment was not blinded to either the participants or investigators because of the differences in how study drug was administered. However, the central imaging laboratory responsible for measuring BMD was blinded to the participant's treatment assignment throughout the study.

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Abaloparatide-SC

Arm description:

Participants self-administered daily doses of abaloparatide 80 micrograms (mcg) subcutaneous (SC) using a single-participant, multiple-use, prefilled injection pen.

Arm type	Experimental
Investigational medicinal product name	abaloparatide
Investigational medicinal product code	
Other name	TYMLOS®, BA058, abaloparatide-SC
Pharmaceutical forms	Solution for injection in pre-filled pen
Routes of administration	Subcutaneous use

Dosage and administration details:

Abaloparatide was administered per dose and schedule specified in the arm description.

<b>Arm title</b>	Abaloparatide-sMTS
------------------	--------------------

Arm description:

Participants self-administered daily doses of abaloparatide solid microstructured transdermal system (sMTS) 300 mcg.

Arm type	Active comparator
Investigational medicinal product name	abaloparatide solid microstructured transdermal system
Investigational medicinal product code	
Other name	BA058, abaloparatide-transdermal
Pharmaceutical forms	Transdermal system
Routes of administration	Transdermal use

Dosage and administration details:

Abaloparatide-sMTS was administered per dose and schedule specified in the arm description.

Notes:

[1] - The roles blinded appear inconsistent with a simple blinded trial.

Justification: Treatment was not blinded to either the participants or investigators because of the

differences in how study drug was administered. However, the central imaging laboratory responsible for measuring BMD was blinded to the participant's treatment assignment throughout the study.

<b>Number of subjects in period 1</b>	Abaloparatide-SC	Abaloparatide-sMTS
Started	255	256
Received at Least 1 Dose of Study Drug	254	252
Completed	191	201
Not completed	64	55
Adverse event, serious fatal	1	-
Consent withdrawn by subject	25	29
Adverse event, non-fatal	29	19
Protocol Deviation	-	2
Significant Deterioration from Baseline of BMD	-	2
Other than Specified	4	1
Lost to follow-up	5	2

## Baseline characteristics

### Reporting groups

Reporting group title	Abaloparatide-SC
Reporting group description: Participants self-administered daily doses of abaloparatide 80 micrograms (mcg) subcutaneous (SC) using a single-participant, multiple-use, prefilled injection pen.	
Reporting group title	Abaloparatide-sMTS
Reporting group description: Participants self-administered daily doses of abaloparatide solid microstructured transdermal system (sMTS) 300 mcg.	

Reporting group values	Abaloparatide-SC	Abaloparatide-sMTS	Total
Number of subjects	255	256	511
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	59	52	111
From 65-84 years	196	204	400
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	68.8	69.3	-
standard deviation	± 6.87	± 6.49	-
Sex: Female, Male Units: participants			
Female	255	256	511
Male	0	0	0
Lumbar Spine BMD T-Score Units: T-Score			
arithmetic mean	-2.569	-2.554	-
standard deviation	± 1.1534	± 1.0997	-

## End points

### End points reporting groups

Reporting group title	Abaloparatide-SC
Reporting group description: Participants self-administered daily doses of abaloparatide 80 micrograms (mcg) subcutaneous (SC) using a single-participant, multiple-use, prefilled injection pen.	
Reporting group title	Abaloparatide-sMTS
Reporting group description: Participants self-administered daily doses of abaloparatide solid microstructured transdermal system (sMTS) 300 mcg.	

### Primary: Percent Change from Baseline in Lumbar Spine BMD at Month 12

End point title	Percent Change from Baseline in Lumbar Spine BMD at Month 12
End point description: Lumbar Spine BMD was assessed by dual energy x-ray absorptiometry (DXA) scans evaluated by a central imaging laboratory.	
End point type	Primary
End point timeframe: Baseline, Month 12	

End point values	Abaloparatide-SC	Abaloparatide-sMTS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	189	200		
Units: percent change				
least squares mean (standard error)	10.8571 ( $\pm$ 0.4755)	7.1361 ( $\pm$ 0.4605)		

### Statistical analyses

Statistical analysis title	Percent Change from Baseline in Lumbar Spine BMD
Statistical analysis description: Percent change from baseline in lumbar spine BMD at Month 12.	
Comparison groups	Abaloparatide-SC v Abaloparatide-sMTS
Number of subjects included in analysis	389
Analysis specification	Pre-specified
Analysis type	non-inferiority <sup>[1]</sup>
Parameter estimate	Least Squares (LSM) Means Difference
Point estimate	-3.721

Confidence interval	
level	95 %
sides	2-sided
lower limit	-5.0089
upper limit	-2.4331

Notes:

[1] - Noninferiority margin = 2.0% for abaloparatide-sMTS compared with abaloparatide-SC. Non-inferiority was to be concluded if the lower bound of the 2-sided 95% CI for the estimated treatment difference (abaloparatide-sMTS minus abaloparatide-SC) in the percent change from baseline in lumbar spine BMD at 12 months was above -2.0% using a Mixed Model for Repeated Measures (MMRM) analysis.

### Secondary: Percent Change from Baseline in Total Hip BMD at Month 12

End point title	Percent Change from Baseline in Total Hip BMD at Month 12
End point description: Total hip BMD was assessed by DXA scans evaluated by a central imaging laboratory.	
End point type	Secondary
End point timeframe: Baseline, Month 12	

End point values	Abaloparatide-SC	Abaloparatide-sMTS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	200		
Units: percent change				
least squares mean (standard error)	3.6995 (± 0.2776)	1.9688 (± 0.2675)		

### Statistical analyses

No statistical analyses for this end point

### Secondary: Percent Change from Baseline in Femoral Neck BMD at Month 12

End point title	Percent Change from Baseline in Femoral Neck BMD at Month 12
End point description: Femoral neck BMD was assessed by DXA scans evaluated by a central imaging laboratory.	
End point type	Secondary
End point timeframe: Baseline, Month 12	



<b>End point values</b>	Abaloparatide- SC	Abaloparatide- sMTS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	188	200		
Units: percent change				
least squares mean (standard error)	3.4159 ( $\pm$ 0.3750)	1.9163 ( $\pm$ 0.3599)		

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Baseline through Month 13

Adverse event reporting additional description:

Safety Population: All randomized participants who received at least 1 dose of study drug.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	24.0
--------------------	------

### Reporting groups

Reporting group title	Abaloparatide-sMTS
-----------------------	--------------------

Reporting group description:

Participants self-administered daily doses of abaloparatide-sMTS 300 mcg.

Reporting group title	Abaloparatide-SC
-----------------------	------------------

Reporting group description:

Participants self-administered daily doses of abaloparatide 80 mcg SC using a single-participant, multiple-use, prefilled injection pen.

Serious adverse events	Abaloparatide-sMTS	Abaloparatide-SC	
Total subjects affected by serious adverse events			
subjects affected / exposed	16 / 252 (6.35%)	19 / 254 (7.48%)	
number of deaths (all causes)	0	1	
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Intraductal proliferative breast lesion			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung adenocarcinoma stage IV			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Invasive ductal breast carcinoma			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transitional cell carcinoma			

subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypotension			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertension			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Pyrexia			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pleural effusion			
subjects affected / exposed	0 / 252 (0.00%)	2 / 254 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Fall			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Femoral neck fracture			

subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tibia fracture			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal compression fracture			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pelvic fracture			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Meniscus injury			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Humerus fracture			
subjects affected / exposed	1 / 252 (0.40%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Head injury			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Bundle branch block left			

subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Coronary artery disease			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac failure			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Metabolic encephalopathy			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Normal pressure hydrocephalus			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transient global amnesia			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Brain oedema			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			

Iridocyclitis			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain upper			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cannabinoid hyperemesis syndrome			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Large intestine polyp			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Small intestinal obstruction			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Cholelithiasis			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Polyarthritis			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Osteoarthritis			

subjects affected / exposed	1 / 252 (0.40%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
COVID-19			
subjects affected / exposed	1 / 252 (0.40%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
COVID-19 pneumonia			
subjects affected / exposed	0 / 252 (0.00%)	2 / 254 (0.79%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastroenteritis			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Metabolism and nutrition disorders</b>			
Hypercalcaemia			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperglycaemia			
subjects affected / exposed	1 / 252 (0.40%)	0 / 254 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 252 (0.00%)	1 / 254 (0.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Abaloparatide-sMTS	Abaloparatide-SC	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	239 / 252 (94.84%)	204 / 254 (80.31%)	
Vascular disorders			
Orthostatic hypotension			
subjects affected / exposed	19 / 252 (7.54%)	20 / 254 (7.87%)	
occurrences (all)	20	27	
Hypertension			
subjects affected / exposed	8 / 252 (3.17%)	15 / 254 (5.91%)	
occurrences (all)	8	16	
Cardiac disorders			
Palpitations			
subjects affected / exposed	6 / 252 (2.38%)	18 / 254 (7.09%)	
occurrences (all)	7	22	
Nervous system disorders			
Headache			
subjects affected / exposed	25 / 252 (9.92%)	41 / 254 (16.14%)	
occurrences (all)	28	46	
Dizziness			
subjects affected / exposed	17 / 252 (6.75%)	24 / 254 (9.45%)	
occurrences (all)	18	28	
General disorders and administration site conditions			
Administration site erythema			
subjects affected / exposed	13 / 252 (5.16%)	4 / 254 (1.57%)	
occurrences (all)	13	4	
Application site swelling			
subjects affected / exposed	116 / 252 (46.03%)	6 / 254 (2.36%)	
occurrences (all)	124	6	
Application site oedema			
subjects affected / exposed	122 / 252 (48.41%)	1 / 254 (0.39%)	
occurrences (all)	128	1	
Application site discolouration			
subjects affected / exposed	37 / 252 (14.68%)	0 / 254 (0.00%)	
occurrences (all)	37	0	
Application site haemorrhage			
subjects affected / exposed	73 / 252 (28.97%)	2 / 254 (0.79%)	
occurrences (all)	78	2	



Application site erythema subjects affected / exposed occurrences (all)	190 / 252 (75.40%) 205	15 / 254 (5.91%) 15
Application site vesicles subjects affected / exposed occurrences (all)	16 / 252 (6.35%) 16	1 / 254 (0.39%) 1
Application site reaction subjects affected / exposed occurrences (all)	18 / 252 (7.14%) 20	0 / 254 (0.00%) 0
Application site pruritus subjects affected / exposed occurrences (all)	83 / 252 (32.94%) 87	10 / 254 (3.94%) 10
Application site pain subjects affected / exposed occurrences (all)	142 / 252 (56.35%) 289	14 / 254 (5.51%) 23
Injection site pain subjects affected / exposed occurrences (all)	17 / 252 (6.75%) 26	82 / 254 (32.28%) 164
Injection site erythema subjects affected / exposed occurrences (all)	26 / 252 (10.32%) 27	119 / 254 (46.85%) 131
Injection site haemorrhage subjects affected / exposed occurrences (all)	6 / 252 (2.38%) 6	30 / 254 (11.81%) 30
Injection site swelling subjects affected / exposed occurrences (all)	10 / 252 (3.97%) 10	48 / 254 (18.90%) 49
Fatigue subjects affected / exposed occurrences (all)	6 / 252 (2.38%) 7	14 / 254 (5.51%) 14
Injection site bruising subjects affected / exposed occurrences (all)	1 / 252 (0.40%) 1	35 / 254 (13.78%) 37
Injection site oedema subjects affected / exposed occurrences (all)	12 / 252 (4.76%) 12	31 / 254 (12.20%) 32

Injection site pruritus subjects affected / exposed occurrences (all)	9 / 252 (3.57%) 9	48 / 254 (18.90%) 51	
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all)	14 / 252 (5.56%) 14	35 / 254 (13.78%) 49	
Renal and urinary disorders Hypercalciuria subjects affected / exposed occurrences (all)	13 / 252 (5.16%) 13	6 / 254 (2.36%) 7	
Musculoskeletal and connective tissue disorders Back pain subjects affected / exposed occurrences (all)  Arthralgia subjects affected / exposed occurrences (all)  Pain in extremity subjects affected / exposed occurrences (all)	14 / 252 (5.56%) 14  25 / 252 (9.92%) 29  11 / 252 (4.37%) 15	26 / 254 (10.24%) 34  20 / 254 (7.87%) 25  17 / 254 (6.69%) 19	
Infections and infestations COVID-19 subjects affected / exposed occurrences (all)  Urinary tract infection subjects affected / exposed occurrences (all)	9 / 252 (3.57%) 10  23 / 252 (9.13%) 27	18 / 254 (7.09%) 18  20 / 254 (7.87%) 20	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
17 June 2019	<ul style="list-style-type: none"><li>• Updated inclusion criterion 3 for previous fractures to clarify that participants were required to meet only 1 and not both of the fracture requirements</li><li>• Added that if sensitization was suspected, the Investigator was to contact the Sponsor for further instructions</li><li>• Removed the requirement for the signing of an additional Informed Consent Form advising participants who sustained an incident fracture and elected to remain in the study that they were at increased risk for a subsequent fracture</li><li>• Added that the radiographs of the lateral thoracic and lumbar spine at Screening would be assessed locally using the Genant Semi-Quantitative Scoring Method</li></ul>
17 June 2019	<ul style="list-style-type: none"><li>• Updated inclusion criterion for postmenopausal women as either a history of amenorrhea for at least 5 years or by an elevated follicle-stimulating hormone (FSH) value <math>\geq 30</math> International units per litre (IU/L)</li><li>• Added that any subject with a thyroid stimulating hormone (TSH) value outside of the normal range was required to have T3 and free T4 tested, with results within the normal range in order to be enrolled</li><li>• Added that bone-specific alkaline phosphatase testing was required only if alkaline phosphatase levels were outside of the normal range</li><li>• Reduced the frequency of 4 hour postdose blood draws for evaluation of calcium</li></ul>
01 October 2019	<ul style="list-style-type: none"><li>• Removed the FSH value <math>\geq 30</math> IU/L from inclusion criterion for postmenopausal women</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

None reported

Notes: